Innate Pharma (NASDAQ:IPHA) Price Target Raised to $9.00

Innate Pharma (NASDAQ:IPHA) had its price objective increased by investment analysts at BTIG Research from $8.00 to $9.00 in a report issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s price target points to a potential upside of 318.60% from the stock’s previous close.

A number of other brokerages have also recently commented on IPHA. HC Wainwright raised their price objective on Innate Pharma from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Monday. Weiss Ratings raised Innate Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 26th. UBS Group reissued a “buy” rating on shares of Innate Pharma in a report on Tuesday. Citigroup upgraded shares of Innate Pharma from a “buy” rating to an “outperform” rating in a research note on Tuesday. Finally, Leerink Partners upgraded Innate Pharma from a “market perform” rating to an “outperform” rating and set a $4.00 price objective on the stock in a research note on Tuesday. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.67.

Innate Pharma Price Performance

IPHA stock opened at $2.15 on Wednesday. The stock has a 50-day moving average price of $1.80 and a 200-day moving average price of $1.67. Innate Pharma has a 1-year low of $1.17 and a 1-year high of $2.62.

Institutional Trading of Innate Pharma

Several institutional investors and hedge funds have recently modified their holdings of the business. Millennium Management LLC bought a new stake in Innate Pharma during the fourth quarter worth about $36,000. OLD Mission Capital LLC bought a new position in shares of Innate Pharma during the fourth quarter valued at about $50,000. Finally, Jane Street Group LLC purchased a new position in Innate Pharma in the 4th quarter worth approximately $162,000. Hedge funds and other institutional investors own 0.16% of the company’s stock.

Innate Pharma News Roundup

Here are the key news stories impacting Innate Pharma this week:

• Positive Sentiment: Strategic Sobi partnership: Innate Pharma and Swedish Orphan Biovitrum (Sobi) agreed to advance lacutamab into a pivotal Phase 3 trial for a rare form of T-cell lymphoma. The deal is expected to provide financing and development support for the cancer therapy, reducing some execution and funding risk. Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer Therapy
• Positive Sentiment: Analyst upgrade: Leerink Partners raised Innate Pharma from “market perform” to “outperform” and assigned a $4.00 price target, signaling considerable potential upside from recent trading levels.
• Positive Sentiment: Long-term earnings outlook improved: HC Wainwright maintained its “Buy” rating and $7.00 target while raising its FY2028 EPS estimate to $(0.15), FY2029 to $0.23, and FY2030 to $0.58. The revisions imply a path to profitability beginning in FY2029.
• Neutral Sentiment: Short-interest data is not meaningful: Reported short interest remained at zero shares, with a zero-day short-interest ratio. This provides little indication of trading pressure because the reported figures show no meaningful short position.
• Negative Sentiment: Near-term earnings estimates were cut: HC Wainwright lowered its FY2026 EPS forecast to $(0.79) from $(0.65) and FY2027 to $(0.59) from $(0.51). These deeper projected losses may be weighing on the stock despite the improved longer-term outlook.

About Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.